[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":500},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,57,82,117,147,179,210,234,261,288,317,350,371,403,425,453,474],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100625089","external-multicenter-validation-of-the-aptto-model-for-prolonged-aptt-using-clot-waveform-analysis-100625089",false,"NCT07418099","External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis","Multicenter External Validation of the APTTO Predictive Model Based on Clot Waveform Analysis for the Assessment of Prolonged Activated Partial Thromboplastin Time","APTTO-EXT","Inclusion Criteria:\n\n1. Patients of any age (pediatric and adult populations) undergoing coagulation testing with:\n\n   \\- Prolonged activated partial thromboplastin time (APTT), defined as an APTT ratio ≥ 1.25.\n\n   \\- Normal prothrombin time (PT), according to local laboratory reference ranges.\n2. Availability of clot waveform analysis (CWA) data obtained during routine APTT testing using:\n\n   * Optical coagulation analyzers (ACL TOP platform).\n   * Silica-based APTT reagent (SynthASil®).\n3. Completion of the standard laboratory evaluation for prolonged APTT as part of routine clinical care, when clinically indicated.\n4. Samples collected and processed in accordance with the standardized preanalytical protocol defined in the study SOP.\n5. Patients evaluated in either:\n\n   * Preoperative assessment, or\n   * Routine clinical practice (non-preoperative setting).\n\nExclusion Criteria:\n\n1. Prolonged prothrombin time (PT) or combined prolongation of PT and APTT.\n\n2- Inadequate preanalytical conditions, defined as non-compliance with the study SOP, including but not limited to:\n\n* Incorrect blood-to-anticoagulant ratio.\n* Delayed plasma processing beyond protocol-defined time limits.\n* Inadequate centrifugation or plasma quality.\n\n  3\\. Absence of required CWA data or unavailable clot waveform images.\n\n  4\\. Samples in which APTT values are outside the measurable range of the analyzer, preventing extraction of CWA-derived parameters.\n\n  5- Patients with missing essential clinical or laboratory data required for application of the APTTO models.","ALL",{"count":19,"type":20},1500,"ESTIMATED","OBSERVATIONAL","Prolonged activated partial thromboplastin time (APTT) is a frequent laboratory finding that may reflect a broad spectrum of underlying conditions, ranging from benign laboratory abnormalities to clinically relevant hemostatic disorders. Clot waveform analysis (CWA), automatically generated during routine APTT testing by optical coagulation analyzers, provides additional quantitative and qualitative information on clot formation dynamics.\n\nThe APTTO model is a previously developed two-step predictive algorithm based on CWA features designed to estimate the probability of a pathological cause of prolonged APTT and to differentiate lupus anticoagulant from intrinsic pathway factor deficiency or von Willebrand disease. Internal validation has demonstrated good discrimination and calibration.\n\nThis multicenter observational study aims to perform an external validation of the APTTO model in independent patient cohorts, assessing its discrimination, calibration, and decision-analytic performance without model updating.",[24,25],"Coagulation Disorder, Blood","Prolonged APTT",[27,25,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Activated Partial Thromboplastin Time","Clot Waveform Analysis","CWA","Preoperative Assessment","Predictive Model","Diagnostic Algorithm","Risk Stratification","Decision Support Systems","Hemostasis","Coagulation Disorders","Lupus Anticoagulant","Coagulation Factor Deficiency","von Willebrand Disease","Laboratory Automation","Clinical Decision-Making","Surgical Delay","Resource Utilization","RECRUITING","2026-04-27",{"date":47,"type":48},"2026-05-01","ACTUAL",{"date":50,"type":48},"2026-01-13",{"date":52,"type":20},"2027-03",{"name":54,"class":55},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","OTHER",16,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":68,"studyType":21,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100634788","prospective-study-of-minimally-invasive-laparoscopic-and-robotic-hernia-repair-incisional-and-primary-midline-and-lateral-not-inguinal-100634788","NCT07544238","Prospective Study of Minimally Invasive (Laparoscopic and Robotic) Hernia Repair (Incisional and Primary, Midline and Lateral, Not Inguinal)","Prospective Study of Minimally Invasive Hernia Repair","PROMISER","Inclusion Criteria:\n\n* Indication for elective minimally invasive ventral hernia repair due to criteria of the participating surgeons\n\nExclusion Criteria:\n\n* Patient rejects participation or giving written informed consent\n* Positive pregnancy test (Beta HCG in serum)\n* Patients who do not meet criteria for minimally invasive surgery due to the criteria of the including surgeon or anesthesiologist (Loss of domain, giant abdominal wall herniae, very small (W1) isolated midline hernia, severe pulmonary or cardiac pathologies)","18 Years",{"count":67,"type":20},400,"5 Years","The participating researchers register all adult patients (who have given informed written consent) scheduled for elective repair of an abdominal wall hernia (NOT inguinal hernias) via minimally invasive operation technique (i.e.: laparoscopy or robotic repair) and perform a follow up of 5 years to analyze clinical outcome parameters. These parameters include recurrence of the hernia, intra- and postoperative complications, quality of live, esthetic outcome and pain.\n\nThe patients will be reviewed in person by the participating researchers at 2-3 moths, 1 year, 3 years and 5 years after surgery. A computed tomography will be performed at 1 year after surgery and in case of suspicion of complications, for example hernia recurrence. The treatment and follow-up of the participating patients does not differ from the standard treatment protocol (and the not participating patients).",[71,72,73],"Ventral Hernia Midline","Hernia Lumbar","Incisional Hernia Repair","2026-04-22",{"date":45,"type":48},{"date":77,"type":48},"2026-04-14",{"date":79,"type":20},"2036-04-14",{"name":54,"class":55},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100631962","phase-4-dual-antiplatelet-therapy-strategies-after-acute-myocardial-infarction-undergoing-pci-prasugrel-vs-ticagrelor--12-months-vs-1-3-months-100631962","NCT07507500","Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months","Strategies for Antiplatelet Management Following Acute Coronary Syndrome","STREAMLINE","Inclusion Criteria:\n\n* ≥18 years old\n* Admitted because of an acute MI (either STEMI or NSTEMI).\n* Invasive management during index admission with successful PCI.\n* Able to consent.\n\nExclusion Criteria:\n\n* Indication for oral anticoagulation therapy.\n* Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor.\n* Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack.\n* Patients with active bleeding or known bleeding disorders.\n* Patients with known moderate or severe hepatic dysfunction (Child-Pugh Class B or Class C).\n* Known intracranial aneurism, arteriovenous malformation or neoplasm.\n* Patients with chronic kidney disease requiring dialysis.\n* Any disorder that may interfere with drug absorption.\n* Pregnancy or current lactation.\n* Concomitant use of potent CYP3A inhibitors or inducers.\n* Planned elective surgery that cannot be deferred 12 months before randomization, requiring interruption of antiplatelet therapy.\n* Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year)\n* Active participation in other clinical trials.",{"count":91,"type":20},8100,"INTERVENTIONAL",[94],"PHASE4","This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.\n\nAfter PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.\n\nThis study is not testing any new intervention, rather comparing approved drugs and approved durations of use.",[97],"Myocardial Infarction (MI)",[99,100,101,102,103,104,105,106],"acute coronary syndrome","infarction","DAPT","dual antiplatelet therapy","prasugrel","ticagrelor","ischemic event","bleeding","NOT_YET_RECRUITING","2026-03-27",{"date":110,"type":48},"2026-04-02",{"date":112,"type":20},"2026-07",{"date":114,"type":20},"2030-01",{"name":54,"class":55},5,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":17,"minAge":65,"maxAge":125,"enrollmentInfo":126,"targetDuration":128,"studyType":21,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100528671","follow-up-of-spanish-prospective-asthma-and-nasal-polyposis-registry-100528671","NCT06163807","Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry","MEGA","Inclusion Criteria:\n\nFor the general asthma cohort (MEGA):\n\n* Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol\u002Fsalbutamol or positive methacholine test) of several severities attended at participant centres\n* Already in follow-up in MEGA cohort\n* To participate in the study\n* Signed informed consent\n\nInclusion criteria for asthma patients treated with biologics\n\n* Patients from 18 to 80 y.o. with uncontrolled asthma with and without nasal polyposis that fulfil criteria to be treated with biological drugs (Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg\u002Fday of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months+ airflow limitation- FEV1 \\\u003C80%\u002FFEV1\u002FFVC \\\u003C70+ACQ-5 score ≥ 1.5\u002F ACT \\\u003C 19 at inclusion and\u002For have experience any of the following events on the last year: treatment with systemic steroids\u002F hospitalization or emergency medical care visit for worsening asthma.\n* When planning dupilumab, mepolizumab, benralizumab or reslizumab, biomarker levels, and exacerbation in the previous year will be considered according to the Spanish Ministry of Health recommendations for reimbursement of any biological drug in severe asthma. In the case of Omalizumab allergic asthma and IgE \\> 75 and \\\u003C 1500 UI\n* Patients already in follow-up in the cohort of patients treated with biologics\n* Willing to participate in the study\n* Sign informed consent\n\nExclusion Criteria:\n\n* Exclusion criteria for MEGA COHORT\n\n  * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function\n  * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders\n  * Patients participating in other clinical trials\n  * Patients without the capacity to understand the aim of the study\n* Exclusion criteria for asthma patients treated with biologics\n\n  * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function\n  * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders\n  * Patients participating in other clinical trials\n  * Patients without the capacity to understand the aim of the study",true,"80 Years",{"count":127,"type":20},1200,"3 Years","Primary objective\n\n\\- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment\n\nSecondary objective(s)\n\n* To study biomarkers variation post-treatment in patients with and without Nasal Polyposis\n* To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous\n* To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).",[131],"Chronic Asthma",[133,134,135,136,137],"asthma","biologics","biomarkers","nasal polyposis","eosinophils","2026-03-25",{"date":140,"type":48},"2026-03-30",{"date":142,"type":48},"2025-02-01",{"date":144,"type":20},"2026-06-02",{"name":54,"class":55},8,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":92,"phases":157,"briefSummary":159,"conditions":160,"keywords":165,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100627220","medication-adherence-in-severe-mental-illness-a-promotion-program-100627220","NCT07445802","Medication Adherence in Severe Mental Illness: a Promotion Program","Therapeutic Adherence Promotion Program for Severe Mental Illness: the ADHERA Study Protocol","ADHERA","Inclusion Criteria:\n\n* Diagnosis established using ICD-11 clinical criteria \\[15\\].\n* Aged 18 years or older.\n* Registered on the Patient Portal.\n* With an active prescription for antipsychotic drugs in the MUP (Medication Use Profile).\n\nExclusion Criteria:\n\n* Aged under 18 years old.\n* Unable to provide consent for medical or legal reasons.\n* Not registered on the Patient Portal.\n* No active prescription for antipsychotic drugs in the MUP.",{"count":156,"type":20},1640,[158],"NA","People living with serious mental illnesses such as schizophrenia and bipolar disorder often need long-term medication to stay well. However, many patients have difficulty taking medication regularly, which can increase the risk of relapse, hospitalization, and poorer quality of life. Traditionally, treatment adherence has been measured using self-report questionnaires, which may be influenced by memory or social desirability bias.\n\nWith the recent expansion of electronic prescription systems in Spain, it is now possible to objectively verify whether patients collect their medications from the pharmacy. This provides a new opportunity to better understand and support treatment adherence.\n\nThe ADHERA study will evaluate how well digital self-report questionnaires reflect real medication use compared with electronic dispensing records. We will also explore patient characteristics that may be associated with difficulties in medication adherence. Finally, we will test a new online psychoeducational program-including sessions led by mental health professionals and supported by peer-experience contributors-to determine whether it can help improve adherence.\n\nParticipants with schizophrenia or bipolar disorder who are registered in the hospital's digital patient portal and have active antipsychotic prescriptions will be invited to complete brief adherence questionnaires online. Individuals with signs of reduced adherence will then be invited to take part in a telehealth intervention consisting of ten group sessions, where they will receive information, support, and practical strategies to maintain their treatment plan. Medication adherence will be reassessed after six months.\n\nIf successful, this study may help improve how treatment adherence is measured in clinical practice, guide targeted interventions for individuals at higher risk of non-adherence, and provide evidence for scalable telehealth programs that can be easily implemented in other regions and medical conditions",[161,162,163,164],"Treatment Adherence and Compliance","Severe Mental Disorders","Bipolar Disorder (BD)","Schizophrenia Disorder",[166,167,168,169,170],"treatment adherence","schizophrenia","bipolar disorder","electronic health records","medication","2026-02-25",{"date":173,"type":48},"2026-03-03",{"date":175,"type":20},"2026-09",{"date":177,"type":20},"2028-09",{"name":54,"class":55},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":81},"100625396","preventing-suicide-with-digital-phenotyping-and-pharmacogenetics-based-interventions-100625396","NCT07422090","Preventing Suicide With Digital Phenotyping and Pharmacogenetics-Based Interventions","Prevention of Suicidal Behavior Through Therapeutic Interventions Guided by Digital Phenotype and Pharmacogenetics: The SMARTomicS Study Protocol","SMARTomicS-R","Inclusion Criteria:\n\n1. At least one suicide attempt in their lifetime.\n2. The attempt must have occurred when the participant was older than 12 years old.\n3. Participants must be at least 18 years old or have parental consent if aged 12-17.\n\nExclusion Criteria:\n\n* medical contraindication prevents blood sample collection\n* unable to provide informed consent to participate in the study","12 Years",{"count":189,"type":20},5000,"The goal of this protocol for an observational retrospective multi-site cohort study is to develop a predictive algorithm for suicidal behavior integrating genetic risk markers, digital phenotypes, and exposomic data in people with a lifetime history of suicide attempt. Participants will be aged from 12 onwards (requiring parental consent if under 18) and only be excluded if they are unable to provide a genetic sample or do not consent to the study. The main question\\[s\\] it aims to answer is:\n\n\\- Can genotyping\u002Fomics analysis of individuals with a history of suicidal behaviuor reveal potential genetic factors associated with suicide risk?\n\nSecondary questions include:\n\n1. Can behavioral factors associated with suicide risk be explored through data obtained from Google Takeout?\n2. Is there an association between medication changes and suicidal behavior, as identified through the Unified Prescription Module and the Digital Health Record?\n3. Do different suicidal phenotypes differ based on the collected variables?\n4. Can the investigators construct an exposome using geolocated and time-stamped data from Google Takeout, combined anonymously with data from the National Statistics and Meteorology Institutes?\n\nThe investigators hypothesize that:\n\n1. Individuals with a history of suicidal behavior will show significant genotypic differences compared to the general population (based on Spanish Genome Project data).\n2. Suicidal phenotypes-especially between single and multiple attempters-will differ across collected variables, including genotype, omics, and exposome data.\n\nparticipants will complete genetic assessments, digital phenotypes, clinical questionnaires and exposomic data",[192],"Suicide Attempt",[194,195,196,197,198,199,200,201],"suicide","suicide attempt","suicidal ideation","phenotyping","digital medicine","eHealth","genetic","exposome","2026-02-18",{"date":204,"type":48},"2026-02-19",{"date":206,"type":48},"2025-04-01",{"date":208,"type":20},"2028-01",{"name":54,"class":55},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":81},"100624986","analysis-of-the-composition-of-the-intestinal-microbiota-in-patients-post-intestinal-anastomosis-100624986","NCT07416760","Analysis of the Composition of the Intestinal Microbiota in Patients Post-intestinal Anastomosis","Analysis of the Composition of the Intestinal Microbiota and Its Evolution in Patients Post-intestinal Anastomosis","MIDESIN","Inclusion Criteria:\n\n* Patients who have undergone colorectal intestinal anastomosis.\n* Signing of the informed consent form.\n* Age ≥18 years with good functional status.\n* Availability for postoperative follow-up.\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Intra-abdominal sepsis or previous dehiscence.\n* Severe immunosuppression.\n* Use of antibiotics in the 3 months prior to preoperative preparation.\n* Pregnancy or breastfeeding.",{"count":219,"type":20},30,"Recent research suggests a significant link between gut microbiota and anastomotic leakage (AL) in colorectal surgery. Patients who develop AL have a higher abundance of bacteria from the Lachnospiraceae family and lower microbial diversity.\n\nConsidering the bibliographic data, our main interest is to analyze the microbial population of patients in our social environment and then look for differences in the microbiome between those who have suffered an anastomotic dehiscence (around 8-9% according to the results of our hospital's Surgery Department) and those who have not.",[222],"Abdominal Surgery",[224,225,226],"Microbiome","intestinal anastomosis","dehiscence","2026-02-13",{"date":202,"type":48},{"date":230,"type":48},"2026-02-14",{"date":232,"type":20},"2026-12-14",{"name":54,"class":55},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":242,"targetDuration":244,"studyType":21,"phases":4,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100617545","descriptive-study-of-circulating-gene-or-protein-inflammatory-biomarkers-and-bioimpedance-parameters-in-a-population-of-patients-hospitalized-for-decompensated-heart-failure-with-preserved-or-mildly-reduced-cardiac-function-100617545","NCT07320014","Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function","Inflammatory Profile in Patients Hospitalized for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Its Correlation With Bioimpedance Parameters and Other Biomarkers With Prognostic Value","BIOFEVIP","Inclusion Criteria:\n\n* Age ≥18 years at recruitment.\n* Signed informed consent.\n* Hospitalization due to decompensated heart failure, based on Framingham criteria and elevated natriuretic peptides (N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) ≥450 pg\u002Fml, or ≥900 pg\u002Fml for patients with atrial fibrillation or flutter).\n* Left ventricular ejection fraction(LVEF) ≥40% and evidence of structural heart disease based on the presence of at least one of the following imaging criteria:\n\n  * Left atrial dilation: LA diameter ≥3.8 cm, or area ≥20 cm², or LA volume ≥55 ml, or indexed LA volume ≥29 ml\u002Fm².\n  * Left ventricular hypertrophy, defined as septal or posterior wall thickness ≥1.1 cm.\n  * Evidence of increased filling pressures, measured by septal or lateral E\u002Fe' ratio \\>15 or \\>12, respectively.\n\nExclusion Criteria:\n\n* Hemodynamic instability at the time of inclusion.\n* Heart failure secondary to acute myocardial infarction (AMI).\n* Pregnant or breastfeeding women.\n* Comorbidities that could influence the clinical course:\n\n  * COPD requiring long-term home oxygen therapy, oral corticosteroids, hospitalization due to exacerbation, or primary pulmonary arterial hypertension.\n  * Chronic treatment with immunosuppressants, corticosteroids, or IL-1 antagonists within the 6 months prior to inclusion.\n  * Confirmed active infection or patients currently receiving antibiotic treatment.\n  * Acute or chronic liver disease.\n  * Chronic kidney disease with eGFR \\\u003C15 ml\u002Fmin\u002F1.73 m² or need for dialysis during hospitalization.\n  * Hematological disorders, such as blood dyscrasias or hemoglobin \\\u003C9 g\u002Fdl on admission.\n  * Active oncological disease, except treated basal cell carcinoma or low-risk prostate cancer.\n  * Patients with limb amputation or carriers of pacemakers or defibrillators (due to possible errors in BIA measurements).\n  * Any disease associated with a life expectancy of less than one year, or patients expected to have difficulty adhering to the study protocol\n* Patients actively participating in other clinical trials involving investigational drugs at the time of inclusion.",{"count":243,"type":20},112,"6 Months","The goal of this observational study is to determine whether changes in the inflammatory profile of heart failure patients can help identify those who may have a worse prognosis or who might benefit more from specific treatments. In addition, we aim to explore whether certain genes or gene mutations are related to a higher risk of future cardiovascular problems.\n\nHeart failure continues to be a major cause of hospital admissions and death in our society. Because of this, it is very important for healthcare professionals to identify which patients are at higher risk of complications, so that we can provide the best possible treatment and follow-up. One method we use to help predict how the disease may evolve is the study of biomarkers, which are measurable biological substances that can help detect, monitor, or treat illnesses in a more personalized way.\n\nIn this study, the investigators will measure mainly inflammatory biomarkers that will be analyzed from a blood sample taken during hospital stay after being diagnosed with heart failure with preserved or mildly reduced ejection fraction. Any important health events that happen during the next six months after patients are discharged from hospital will also be recorded.\n\nIn addition, it is known that more than 2,000 diseases are known to be caused by changes in specific genes. In the case of cardiomyopathies-heart muscle diseases that can lead to heart failure-genetic causes vary depending on the type, and studies suggest that between 10% and 50% of cases may have a genetic origin. Identifying genetic markers linked to heart failure with preserved or mildly reduced ejection fraction may help improve prevention, treatment, and risk assessment, as some genetic changes may be associated with repeated cardiovascular events. By studying not only circulating biomarkers but also genetic factors, the investigators hope to better understand whether certain gene alterations may increase a person's tendency to experience additional heart-related events.\n\nThis is an observational study, which means that medical care and treatment will be exactly the same whether patients choose to participate or not. Participation involves allowing researchers to collect relevant information from medical records and agreeing to the collection of two or three small additional blood samples for research purposes. These samples will be used to measure the biomarkers and to analyze genes in the white blood cell fraction obtained from the same tubes.",[247,248],"Inflammation Biomarkers","Heart Failure",[250,251,252,253],"inflammatory profile","heart failure with preserved ejection fraction","heart failure with mildly reduced ejection fraction","bioimpedance","2025-12-20",{"date":256,"type":48},"2026-01-06",{"date":258,"type":20},"2026-01",{"date":208,"type":20},{"name":54,"class":55},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":92,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":81},"100593197","anterior-versus-posterior-white-line-advancement-technique-in-the-correction-of-aponeurotic-ptosis-100593197","NCT07003308","Anterior Versus Posterior White Line Advancement Technique in the Correction of Aponeurotic Ptosis","Comparative Study of the Efficacy of Anterior Versus Posterior White Line Advancement Technique in the Correction of Primary Aponeurotic Ptosis","Inclusion Criteria:\n\n* Age over 18 years.\n* Diagnosis of primary aponeurotic upper eyelid ptosis.\n* Levator muscle function of 12 mm or greater.\n* Provision of written informed consent after receiving adequate information about the study.\n\nExclusion Criteria:\n\n* Diagnosis of non-aponeurotic eyelid ptosis.\n* Poor levator muscle function.\n* History of recurrent eyelid ptosis or previous eyelid ptosis surgery.\n* Medical or surgical history that, in the investigator's judgment, may interfere with participation.\n* Individuals with childbearing potential who are not using highly effective contraception methods.\n* Refusal to participate in the study or to sign the informed consent form.",{"count":269,"type":20},54,[158],"The goal of this clinical trial is to compare the efficacy of two surgical techniques-anterior and posterior white line advancement-for the correction of primary aponeurotic ptosis in adult patients. The main questions it aims to answer are:\n\nDoes the anterior approach lead to a greater improvement in Marginal Reflex Distance 1 (MRD1) at 6 months compared to the posterior approach?\n\nAre there differences in eyelid symmetry, contour, visual function, and patient satisfaction between the two techniques?\n\nResearchers will compare the anterior approach group to the posterior approach group to see if one offers better functional and aesthetic outcomes, fewer complications, or higher patient satisfaction.\n\nParticipants will:\n\nBe randomly assigned to receive either anterior or posterior white line advancement surgery.\n\nUndergo preoperative and postoperative evaluations at 7 days, 2 months, and 6 months, including:\n\nMeasurements of eyelid position (MRD1), contour, and symmetry\n\nVision and tear film tests (e.g., refraction, TBUT, Schirmer's test)\n\nSurveys on dry eye symptoms (OSDI), scar quality (POSAS 2.0), satisfaction, and psychosocial function\n\nMonitoring of surgical time and complications",[273],"Ptosis, Eyelid",[275,276,277,278,279],"eyelid","levator palpebrae","oculoplastic surgery","ophthalmology","blepharoptosis","2025-10-02",{"date":282,"type":48},"2025-10-07",{"date":284,"type":48},"2025-06-01",{"date":286,"type":20},"2027-01-30",{"name":54,"class":55},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":295,"minAge":65,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":92,"phases":299,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":4},"100484241","a-laser-and-topical-treatment-combination-in-the-vulvo-vaginal-atrophy-management-in-breast-cancer-patients-100484241","NCT05585476","A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.","Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.","Inclusion Criteria:\n\nPatients must meet ALL of the following criteria to be included in the study:\n\n1. Patients over 18 years of age\n2. Who have a history of breast malignancy, and are on adjuvant or neoadjuvant treatment with hormone therapy.\n3. That they suffer symptoms related to vulvo-vaginal atrophy and thus become evident to the gynecological examination (Vaginal Health Index\\\u003Có=15).\n4. That this clinic significantly affects your quality of life ( score in Sexual Function-Vaginal Changes Questionnaire less than or equal to 24 points).\n5. Who have not received any treatment for vulvo-vaginal atrophy in at least the previous 6 months. Purely moisturizing or emollient treatments that do not contain any regenerating substance (hyaluronic acid, gotu kola, vitamin E or rosehip oil) are not considered exclusive.\n6. That they agree to participate and give their written I consent.\n\nExclusion Criteria:\n\nPatients who present ANY of the following criteria may not be selected to participate in this study:\n\n1. Medical or surgical history that at the discretion of the researcher does not allow participation in the study.\n2. Refusal to participate in the study and to sign consent.\n3. Be on chemotherapy treatment at the time of inclusion in the study.\n4. Have completely completed the adjuvant hormonal treatment.\n5. Have a history of vulvar, vaginal and\u002For cervical malignancy.\n6. Have received radiation therapy to the pelvic and\u002For genital region.\n7. Sjögren's syndrome and other pathologies that occur with mucosal involvement.\n8. Present any type of disease that occurs with alteration of collagenogenesis.\n9. Intake of other cytotoxic drugs that lead to mucositis and alterations of tissue regeneration in the last 6 months.\n10. Have previously received laser and\u002For radiofrequency treatment for the treatment of genital atrophy or other pelvic floor dysfunctions.\n11. Active urinary and\u002For genital tract infection.\n12. Diagnosis of gestation at the time of recruitment.\n13. History of malignant neoplasm of the urinary tract.\n14. Have severe stress urinary incontinence (Sandvik test with a score equal to or greater than 8)\n15. Diagnosis of pelvic organ prolapse grade III or higher according to the POP-Q classification.\n16. Any other condition which, in the opinion of the investigator, means that the patient is not in a position to understand the implication of participating in the study and\u002For of following the established procedures.","FEMALE","100 Years",{"count":298,"type":20},180,[158],"The genito-urinary syndrome of menopause severely affects patients with a history of gynecological cancer, especially those diagnosed with breast cancer. At the present time, we do not have solid scientific evidence on treatments that can be effective and safe to address this pathology. Based on the above, we have developed our working hypothesis where it is postulated that the microfractionated laser treatment of C02, in conjunction with topical regenerative treatment, constitute an effective alternative in the management of vulvo-vaginal atrophy in oncological patients who have contraindicated hormonal treatments.",[302,303],"Female Urogenital Diseases","Breast Cancer Female",[305,306,307,308,309],"Vulvovaginal atrophy","Breast cancer","Hormone therapy","Regenerative topical treatment","C02 microfractionated laser","2025-09-15",{"date":312,"type":48},"2025-09-19",{"date":314,"type":20},"2025-10",{"date":175,"type":20},{"name":54,"class":55},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":295,"minAge":65,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":92,"phases":327,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":349},"100595636","evaluation-of-the-fetal-response-to-intrapartum-digital-fetal-scalp-stimulation-to-identify-intrapartum-fetal-hypoxia-100595636","NCT07035028","Evaluation of the Fetal Response to Intrapartum Digital Fetal Scalp Stimulation to Identify Intrapartum Fetal Hypoxia.","Evaluation of Fetal Response to Intrapartum Digital Fetal Scalp Stimulation Upon Detection of Suspected Loss of Fetal Well-being in Suspicious and Pathologic Cardiotocographic Recordings, to Identify Intrapartum Fetal Hypoxia.","Inclusion criteria:\n\nWomen with singleton pregnancy.\n\nCephalic presentation.\n\nGestational age greater than or equal to 37 weeks.\n\nPathological cardiotocographic record according to the criteria published by FIGO and with indication to perform a second-line complementary test, in our case a gold standard test of fetal scalp blood FBS, which confirms or not if there is a risk of loss of fetal well-being and the need for fetal extraction.\n\nSignature of HIP and CI for data collection.\n\nExclusion criteria:\n\nUnder 18 years of age.\n\nContraindication for FBS\n\nUterine dilatation that does not make FBS possible.\n\nHIV\n\nHepatitis\n\nFetuses at increased risk of hemorrhage.","50 Years",{"count":326,"type":20},182,[158],"The main objective of this study is to evaluate whether digital fetal scalp stimulation improves fetal well-being in fetuses with suspicious or pathological cardiotocographic recordings, showing an improvement in cardiotocographic recording patterns and normal values in intrapartum fetal scalp blood results.\n\nUpon detection of a suspicious or pathologic cardiotocographic recording, the investigators need to perform an objective verification of fetal well-being.\n\nCurrently, fetal scalp blood is the reference test to assess intrapartum fetal hypoxia, according to the protocols of the Spanish Society of Gynecology and Obstetrics.\n\nThis procedure lasts about 5 minutes and consists of taking a small sample of the fetal scalp, through a vaginal exploration, the blood is collected in a thin tube and analyzed by a machine in the delivery room obtaining the results in a few minutes.\n\nThe investigators emphasize that this test is not part of the study, as long as the monitor is suspicious or pathological, it will be performed according to protocol to objectively assess fetal well-being.\n\nCurrently there are studies that support the use of fetal scalp stimulation as an alternative technique to assess intrapartum fetal well-being and predict neonatal outcomes, but they also highlight its limited evidence.\n\nDigital fetal scalp stimulation is a NON-invasive method, as no instrument is required and fetal stimulation is a 30-60 second surface rubbing pressure, which is performed manually, through vaginal exploration, the same technique the investigators use to assess dilation during the labor process.\n\nEach patient will be randomly assigned to a study group:\n\nExperimental group: before the extraction of capillary blood from the fetal scalp, fetal head stimulation will be performed, a technique that poses no risk to the baby. The researchers need the consent of the participants to perform this technique and collect data.\n\nControl group: fetal head stimulation will not be applied, but data from the clinical history necessary for this study will be collected.\n\nIn no case will extraordinary or unnecessary tests be performed for participation in this study.\n\nThis study will have an Informed Consent document.\n\nThis study will be carried out at the Fundación Jiménez Díaz and Zarzuela and will include 182 patients for 24 months.",[330,331],"Fetal Hypoxia","Fetal Monitoring",[333,334,335,336,337,338,339,340],"digital fetal scalp stimulation dFSS","fetal monitoring","fetal blood sampling FBS","fetal scalp blood","cardiotocography","umbilical cord blood","acidemia","Intrapartum care","2025-06-16",{"date":343,"type":48},"2025-06-24",{"date":345,"type":48},"2024-01-01",{"date":347,"type":20},"2025-12",{"name":54,"class":55},2,{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":295,"minAge":65,"maxAge":324,"enrollmentInfo":357,"targetDuration":4,"studyType":92,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":81},"100591073","open-non-comparative-pilot-study-to-evaluate-the-safety-and-efficacy-of-intraovarian-plasma-rich-in-growth-factors-prgf-in-patients-with-low-ovarian-reserve-100591073","NCT06975683","Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRGF) in Patients With Low Ovarian Reserve","Open, Non-comparative, Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Growth Factor-rich Plasma in Patients With Low Ovarian Reserve","Inclusion Criteria:\n\n* Women of childbearing age as defined by the CTFG\\*.\n* Women in group 3 and 4 of the POSEIDON classification for low reserve:\n* POSEIDON 3: patients ˂ 35 years of age with decreased ovarian reserve (AMH \\\u003C1.2 ng\u002Fml, AFC \\\u003C5).\n* POSEIDON 4: patients ≥ 35 years with decreased ovarian reserve (AMH \\\u003C1.2 ng\u002Fml, AFC \\\u003C5).\n* Patients with at least one ovary.\n* Infertility of more than 1 year duration.\n* Provision of safe ovarian access on the day of the puncture.\n* They agree to participate and to give their written consent.\n\nExclusion Criteria:\n\n* Have a diagnosis of clinical ovarian insufficiency - Patients with an ongoing pregnancy - Patients with a clinical diagnosis of ovarian failure\n* Patients with ongoing pregnancy\n* Current or previous IgA deficiency,\n* Ovarian failure secondary to identified genetic causes.\n* Presence of pelvic adhesions after abdominal surgery.\n* Chronic use of aspirin, NSAIDs or anticoagulants.\n* Diseases that alter platelet number or function.\n* Psychiatric disorder that precludes participation in the study (including active substance abuse or dependence).\n* Obesity (BMI ≥ 30).\n* Current female smokers (≥ 15 cigarettes per day) - Current smoking (≥ 15 cigarettes per day)\n* Patients affected by neoplastic disease\n* Severe male factor infertility",{"count":358,"type":20},50,[158],"The use of plasma rich in growth factors (PRGF) improves ovarian reserve markers and IVF laboratory parameters in women with low ovarian reserve.\n\nPrimary objective To compare ovarian reserve markers and IVF-ICSI laboratory results before and after PRGF infusion.\n\nSecondary Objectives\n\n* To compare pre- and post-treatment pregnancy rates.\n* To collect complications associated with the application of intraovarian PRGF. General Outline of the Study VISIT 1\n* Patient Selection\n* Confirm that he\u002Fshe has all the analyses and variables to be studied.\n* Signing of Informed Consent\n* Usual IVF protocol (1st IVF cycle) VISIT 2\n* Instillation of intraovarian PRGF on the day of the puncture of the 1st IVF cycle in the FJD VISIT 3\n* Analytical control at 4 weeks VISIT 4\n* Analytical control at 8 weeks VISIT 5\n* In case of failure to achieve gestation Start of 2nd cycle of IVF",[362],"Low Ovarian Reserve","2025-06-11",{"date":365,"type":48},"2025-06-12",{"date":367,"type":48},"2025-05-30",{"date":369,"type":20},"2026-05",{"name":54,"class":55},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":92,"phases":381,"briefSummary":384,"conditions":385,"keywords":388,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":81},"100590483","phase-1-double-blind-pilot-study-on-the-effect-of-anionic-exposome-enrichment-biow-on-recovery-and-sleep-quality-in-postoperative-patients-100590483","NCT06968000","Double-blind Pilot Study on the Effect of Anionic Exposome Enrichment (Biow) on Recovery and Sleep Quality in Postoperative Patients","Pilot, Controlled, Double-blind Study to Evaluate the Effect of the Exposome Anionic Enrichment System (Biow) on Hospital Recovery Quality, Clinical Response, and Sleep Quality in Postoperative Patients","EOX","Inclusion Criteria:\n\n* Adults aged ≥18 years, regardless of sex.\n* Undergoing elective general surgery, preferably hepatobiliary procedures.\n* Hospitalized for at least 4 days postoperatively in Unit 69 (HUFJD).\n* Able to provide written informed consent.\n* Considered to have medium or high risk of oxidative stress or mitochondrial dysfunction.\n\nExclusion Criteria:\n\n* Surgery within the previous 6 months, either outpatient or inpatient.\n* Diagnosed psychiatric or neurological disorders, including epilepsy.\n* Active progressive cancer or chronic inflammatory disease.\n* Cognitive impairment or inability to comply with study procedures.\n* BMI ≥30 kg\u002Fm² (obesity class I or higher).",{"count":380,"type":20},150,[382,383],"PHASE1","PHASE2","Airborne nanoparticle exposure is increasingly recognized as a significant contributor to oxidative stress, mitochondrial dysfunction, and low-grade systemic inflammation-factors that impair postoperative recovery. The World Health Organization and European initiatives such as the Human Exposome Project have highlighted the clinical importance of the exposome, defined as the totality of environmental exposures influencing health throughout life.\n\nEOX is a CE-certified air regeneration system designed to modify the indoor exposome through a dual mechanism: advanced filtration and controlled emission of bioavailable anions using cold atmospheric plasma (CAP). Its multistage filter removes particulate matter, pathogens, and volatile organic compounds, while the anionic plasma phase modulates cellular oxidative balance and metabolic function.\n\nExperimental and clinical data indicate that exposure to EOX improves mitochondrial efficiency, increases ATP production, and reduces oxidative protein damage. EOX has also been shown to influence molecular pathways involved in stress adaptation and repair, such as the HIF-1α-VEGF-EPO axis and protein synthesis signaling (e.g., mTOR-p70S6K). These mechanisms may collectively enhance tissue recovery, vascularization, and metabolic resilience in the postoperative setting.\n\nThe present study investigates the effects of EOX in hospitalized postoperative patients, evaluating both subjective (sleep quality, well-being) and objective (vital signs, metabolomics, microbiota composition) endpoints. The central hypothesis is that EOX induces a beneficial hormetic response-an adaptive reaction to mild environmental stressors-reflected by improved clinical recovery and biomarker modulation (e.g., succinate reduction, increased ATPase activity). The goal is to assess whether EOX can serve as an effective environmental intervention to support physiological healing and improve the quality of inpatient recovery.",[386,387],"Inflammatory Response After Surgery","Postoperative Recovery",[389,390,391,392,393,394],"Exposome","Bioavailable anions","Postoperative recovery","Mitochondrial function","Oxidative stress","Surgical inflammation","2025-05-05",{"date":397,"type":48},"2025-05-13",{"date":399,"type":48},"2025-03-01",{"date":401,"type":20},"2027-03-01",{"name":54,"class":55},{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":295,"minAge":324,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":92,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":424},"100572846","phase-1-allogeneic-use-of-expanded-mesenchymal-stem-cells-derived-from-adipose-tissue-hc106-female-urinary-incontinence-women-over-50-years-old-100572846","NCT06738576","Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old","Phase II Clinical Trial to Determine the Safety and Efficacy of the Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106) in the Local Treatment of Female Urinary Incontinence in Women Over 50 Years of Age","SUITH)","Inclusion Criteria:\n\n* Women over 50 years old\n* Women with a clinical diagnosis of genuine or mixed stress urinary incontinence (SUI) with at least 6 months of evolution. Using the definitions of urinary incontinence internationally accepted by the ICS (International Continence Society): to. SUI: any involuntary loss of urine, immediately preceded by exertion. b. Mixed UI: any involuntary loss of urine, immediately preceded by exertion or an uncontrollable desire to urinate.\n\nThe predominance of effort will be assessed when more than 50% of the patient's daily losses occur preceded by effort.\n\n* Women in whom rehabilitative treatment has failed or patients who refuse to undergo rehabilitative or surgical treatment\n* Patients without active urinary tract infection (negative urine culture) at the time of recruitment and treatment\n* Signing of the informed consent form\n\nExclusion Criteria:\n\n* Patients with a medical history of previous surgery for incontinence, prolapse or urological\u002Fgynecological\u002Fcolorectal surgery\n* Major surgery or serious trauma of the subject in the previous semester\n* Women with mixed urinary incontinence, with predominant symptoms of urgency\n* History of high-pressure detrusor overactivity\n* Present infravesical obstruction, vesico-ureteral reflux or clinical history of urinary fistula (it will be ruled out depending on the case by urethrocystoscopy, urethrocystography and flowmetry).\n* Present any malignant neoplasm, unless it is basal cell or squamous cell carcinoma of the skin, or present a history of malignant tumors, unless they have been in remission during the previous 5 years.\n* Cardiopulmonary disease that, in the opinion of the investigator, is unstable or serious enough to exclude the patient from the study.\n* Medical or psychiatric illness of any type that, in the opinion of the researcher, may be a reason for exclusion from the study.\n* History of alcohol or other addictive substance abuse in the 6 months prior to inclusion\n* Subject's allergy to anesthetics",{"count":412,"type":20},60,[382],"Evaluate the feasibility and safety, obtaining initial efficacy data, of expanded allogeneic mesenchymal stem cells derived from adipose tissue (HC106) for the treatment of urinary incontinence in women over 50 years of age.",[416],"Urinary Incontinence Stress","2025-04-29",{"date":419,"type":48},"2025-05-01",{"date":421,"type":48},"2024-12-16",{"date":347,"type":20},{"name":54,"class":55},6,{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":433,"maxAge":434,"enrollmentInfo":435,"targetDuration":437,"studyType":21,"phases":4,"briefSummary":438,"conditions":439,"keywords":443,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":349},"100569141","deprecap-lung-cancer-screening-programme-by-ldct-for-patients-with-copd-or-emphysema-100569141","NCT06690385","DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.","Registry of Patients Included in the DEPRECAP (Lung Cancer Screening Porgramme by Low-dose Computed Tomography for Patients With Chronic Obstructive Pulmonary Disease (COPD) or Emphysema.","DEPRECAP","Inclusion Criteria:\n\n* Current or former smokers (\\>15 years of abstinence) with a cumulative smoking exposure of \\> 30 pack-years\n* Diagnosis of COPD according to the GOLD guidelines and\u002For emphysema identified by LDCT and\u002For a carbon monoxide diffusing capacity (DLCO) lower than 80% of predicted (as per the Global Lung Function Initiative (GLI) equations)\n\nExclusion Criteria:\n\n* Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded from the study.","55 Years","75 Years",{"count":436,"type":20},1998,"40 Years","The DEPRECAP (Early detection of lung cancer) study is an ongoing, prospective, longitudinal, multicenter lung cancer screening program that recruited individuals with COPD or emphysema from the pulmonary clinics of Fundación Jiménez Díaz University Hospital and Villalba General Hospital, in Madrid, Spain.\n\nThe aim of this observational study is to determine the scientific evidence needed to study the benefit and potential effects of lung cancer screening in this group of patients and to determine the long-term effects of the intervention in reducing the high mortality rates associated with late-stage lung cancer diagnosis in a very high-risk population, to address under-diagnosis of COPD and to promote smoking cessation. This leads to the creation of a registry with clinical, radiological, functional data and biological samples for future studies in this cohort of patients to provide the scientific evidence needed to study the benefit and potential effects of screening for lung cancer and other tobacco-related pathologies diagnosed by Low-dose CT (LDCT)",[440,441,442],"Lung Cancer","COPD","Emphysema",[444,445,441,442],"Lung cancer screening","Low-dose computed CT","2024-11-13",{"date":448,"type":48},"2024-11-15",{"date":450,"type":48},"2014-01-14",{"date":446,"type":20},{"name":54,"class":55},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":81},"100567365","impact-on-quality-of-life-and-burden-of-disease-in-adults-with-herpes-zoster-100567365","NCT06667245","Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster","1 Prospective cohort study Inclusion criteria Patients \\> 18 years of age who are to be immunized against HZ\n\nExclusion criteria:\n\n* Pregnant women\n* Patients with altered level of consciousness (dementia and others) who do not complete the questionnaires\n* Patients who do not wish to participate in the study 5.2 Retrospective cohort study Inclusion criteria Adults \\>18 years of age with a diagnosis of HZ in the CMBD from 2012 to 2023 at the Jiménez Díaz Foundation hospital. Since the international classification of diseases changed from ICD 9 to ICD 10 in 2106, the codes to be used for the inclusion of patients in the study are described below.\n\nICD 9 053 Herpes zoster\n\nIncludes:\n\n* Herpes zoster\n* Zone 053.0 With meningitis 053.1 With other central nervous system complications\n* 053.10 With unspecified nervous system complications\n* 053.11 Geniculate herpes zoster or Herpetic geniculate ganglionitis\n* 053.12 Postherpetic trigeminal neuralgia\n* 053.13 Postherpetic polyneuropathy\n* 053.14 Herpes zoster myelitis\n* 053.19 Other 053.2 With ophthalmic complications\n* 053.20 Herpes zoster dermatitis of eyelid or Herpes zoster ophthalmicus\n* 053.21 Herpes zoster keratoconjunctivitis\n* 053.22 Herpes zoster iridocyclitis zoster\n* 053.29 Other 053.7 With other specific complications\n* 053.71 Otitis externa due to herpes zoster\n* 053.79 Other 053.8 With unspecified complications 053.9 Herpes zoster without complication Herpes zoster NOS ICD 10 B02 Herpes zoster\n\nIncludes:\n\n* herpes\n* zona B02.0 Encephalitis due to herpes zoster Meningoencephalitis due to zoster B02.1 Meningitis due to herpes zoster B02.2 Herpes zoster with other nervous system involvement\n* B02.21 Postherpetic geniculate ganglionitis\n* B02.22 Postherpetic trigeminal neuralgia\n* B02.23 Postherpetic polyneuropathy\n* B.02.24 Myelitis Postherpetic myelitis\n* B02.29 Other postherpetic nervous system involvement\n* B02.3 Ocular herpes zoster\n* B02.30 Ocular herpes zoster, unspecified\n* B02.31 Herpes zoster conjunctivitis\n* B02.32 Herpes zoster iridocyclitis\n* B02.33 Herpes zoster keratitis\n* B02.34 Herpes zoster scleritis\n* B02.39 Other herpes zoster eye disease\n* B02.7 Disseminated herpes zoster\n* B02.8 Herpes zoster with other complications\n* B02.9 Uncomplicated herpes zoster\n* B02.39 Herpes zoster otitis externa NEOM\n\nExclusion criteria:\n\nPatients who are vaccinated against HZV",{"count":460,"type":20},357,"Title: Impact on quality of life and disease burden in adults with herpes zoster\n\nProspective cohort study for the primary objective and the secondary objectives (1 and 2) and retrospective cohort study for the secondary objective 3.\n\nDisease or disorder under study: Patients with a herpes zoster (HZ) diagnosis.",[463,464,465],"Herpes Zoster","Quality of Life","Immunization; Infection","2024-10-30",{"date":468,"type":48},"2024-10-31",{"date":470,"type":20},"2024-11-04",{"date":472,"type":20},"2026-11-04",{"name":54,"class":55},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":81},"100527192","response-to-upadacitinib-of-enthesitis-evaluated-by-ultrasound-in-patients-with-psoriatic-arthritis-100527192","NCT06144567","Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis","Ultrasound-based Response of Enthesitis to Upadacitinib in Psoriatic Arthritis","Inclusion Criteria:\n\n* Adult male or female, at least ≥ 18 years old and ≤ 65 years old at Screening.\n* Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening visit and fulfillment of the Classification Criteria for PsA (CASPAR) (19).\n* Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.\n* Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies.\n* Inadequate response or intolerance to at least one bDMARD, one of them must be an anti-TNF according to the Spanish regulatory and reimbursement policies (\"informe de posicionamiento terapéutico\").\n* Patients should have at least one ultrasound-determined peripheral enthesitis site according to OMERACT definition for ultrasound enthesitis.\n* Subjects must voluntarily sign and date an informed consent.\n\nExclusion Criteria:\n\n* Patients who cannot be treated with upadacitinib according to the approved label (e.g., contraindications).\n* Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive upadacitinib.\n* Unwillingness or inability to comply with the study requirements.\n* Prior exposure to any Janus kinase (JAK) inhibitor.\n* Patients taking ≥ 10 mg of prednisone or equivalent","65 Years",{"count":483,"type":20},19,"Primary objective To evaluate the peripheral enthesitis response to upadacitinib treatment by BMUS and DMUS, in PsA patients at week 24.\n\nSecondary objective:\n\n1. To evaluate the peripheral enthesitis response to upadacitinib treatment by BMUS and DMUS, in PsA patients at week 12.\n2. To evaluate the clinical response of enthesitis to upadacitinib by LEI, at week 12 and week 24.\n3. To evaluate the clinical response of disease activity by DAPSA, at week 12 and week 24.\n\nStudy Design: single-arm, observational longitudinal, prospective study\n\nPopulation: The study population will consist of adult patients (aged ≥ 18 years old and ≤ 65 years old) with PsA according to CASPAR classification criteria, who have been prescribed upadacitinib over the course of routine practice, in accordance with the applicable approved label and local regulatory and reimbursement policies (\"In patients with psoriatic arthritis, upadacitinib would be a therapeutic alternative after failure, inadequate response or intolerance to csDMARDs and anti-TNF\") and have at least one ultrasound-determined peripheral enthesitis.",[486],"Psoriatic Arthritis",[488,489,490,491],"Ultrasound","Entheses","Psoriatic arthritis","Upadacitinib","2023-11-25",{"date":494,"type":48},"2023-11-29",{"date":496,"type":20},"2023-12",{"date":498,"type":20},"2026-06",{"name":54,"class":55},""]